Lean mass loss during GLP-1-driven weight loss is well documented, but the framing of that finding matters. In the STEP-1 body composition substudy of semaglutide, roughly 40–45% of total weight lost was lean mass, with total lean mass falling about 10–13% from baseline.[1] In the SURMOUNT-1 body composition substudy of tirzepatide, the lean mass fraction of total weight lost was somewhat lower, around 25%.[1] Neither figure is unique to GLP-1 medications specifically — similar or greater lean mass loss occurs with very-low-calorie diets and bariatric surgery, since rapid calorie restriction from nearly any source pulls some muscle along with fat.
What actually mitigates it: exercise intervention data
A trial (NCT04122716) combining liraglutide with supervised resistance and aerobic training produced a genuinely notable result: participants didn't just lose less lean mass than pharmacotherapy alone — they gained lean mass, alongside superior overall weight loss compared to either intervention independently.[2] This is a materially different and more encouraging finding than "resistance training reduces the rate of muscle loss" — it suggests the combination can produce net muscle gain even during significant fat loss.
Combining liraglutide with supervised resistance and aerobic training not only produced superior weight loss but enabled patients to actually gain lean mass, an outcome not seen with pharmacotherapy alone.
Protein intake targets
At the ADA 2026 Scientific Sessions symposium on GLP-1 receptor agonists, presenting experts cited evidence supporting a protein intake range of 1.2 to 1.6 g/kg body weight per day as the effective target for muscle preservation, with diminishing returns observed above that threshold.[3] This range is consistent with broader sports nutrition and sarcopenia-prevention literature outside the GLP-1-specific context.
Pharmacological adjuncts: the BELIEVE trial
The Phase 2 BELIEVE trial (NCT05616013) combined semaglutide with bimagrumab, a myostatin pathway inhibitor, specifically to test whether blocking a key negative regulator of muscle growth could preserve lean mass during GLP-1-driven weight loss.[3] The results were substantial: the lean mass fraction of total weight loss dropped from roughly 21% with semaglutide monotherapy to approximately 7% with the combination.
The persistent gap: functional outcomes
Despite the growing body composition (DXA-based) data, one expert at the ADA 2026 symposium specifically flagged the absence of large-scale trials examining actual muscle function — strength, mobility, physical performance — as opposed to simply measuring lean tissue mass on a scan.[3] A DXA scan showing preserved lean mass doesn't automatically confirm that mass is functionally equivalent to what existed before treatment; grip strength, timed chair-rise tests, and similar functional measures remain comparatively understudied in this specific context.
Why population context changes the picture
Most of the higher-percentage lean mass loss figures come from trials in populations with obesity, often less physically active at baseline. Reporting from clinical practice suggests overweight-but-not-obese individuals, or those already engaged in regular resistance training with adequate protein intake before starting therapy, tend to show meaningfully better lean mass preservation — though this observation comes primarily from clinical experience and smaller cohort data rather than large randomized trials specifically designed to test baseline-activity-level as a moderating variable.
What's currently being studied
The FLEX study (NCT07457437), a randomized parallel-group trial at the University of Exeter, began enrollment in April 2026 and is specifically testing a progressive resistance exercise program's effect on muscle mass and physical function during tirzepatide-induced weight loss in overweight and obese women.[4] With an estimated completion date of December 2027, this is one of the more direct tests to date of the resistance-training-plus-GLP-1 combination specifically designed with functional outcomes in scope, not just body composition scans.
Bimagrumab and other myostatin-pathway adjuncts remain investigational — the BELIEVE trial is Phase 2 data, not an approved combination therapy, and the timeline to any potential approval, if the approach continues to Phase 3 successfully, would extend years beyond current data.
Compare GLP-1 telehealth providers
Source GLP-1 tracks pricing, licensing, and provider structure across the market.